Order Article Reprints

Bamodu OA, Tzou K-Y, Lin C-D, Hu S-W, Wang Y-H, Wu W-L, Chen K-C, Wu C-C. Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer. Cancers. 2021; 13(14):3478. https://doi.org/10.3390/cancers13143478

Bamodu, Oluwaseun Adebayo, Kai-Yi Tzou, Chia-Da Lin, Su-Wei Hu, Yuan-Hung Wang, Wen-Ling Wu, Kuan-Chou Chen, and Chia-Chang Wu. 2021. "Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer" Cancers 13, no. 14: 3478. https://doi.org/10.3390/cancers13143478

Bamodu, O. A., Tzou, K.-Y., Lin, C.-D., Hu, S.-W., Wang, Y.-H., Wu, W.-L., Chen, K.-C., & Wu, C.-C. (2021). Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer. Cancers, 13(14), 3478. https://doi.org/10.3390/cancers13143478